Penn Spinout Gemma Therapeutics Raises $34 million to Develop Gene Therapies for Rare Diseases
Gemma Bio raised $34 million in a seed round led by Double Point Ventures, Bioluminescence Ventures and Earlybird Venture Capital.
Stentix Awarded 2025 Y-Prize
Stentix won the 2025 Y-Prize competition after presenting their business plan for a bile duct stent that can be adjusted noninvasively to help patients maintain bile flow without further surgical inte
PCI’s 10th Anniversary Highlighted in Penn Today
PCI was featured as the lead story in the January 17th issue of Penn Today in recognition of its 10-year anniversary.
Innovating for Impact: Highlights from the Fall 2024 Penn I-Corps Cohort
Eight teams completed the program, and 26 individuals received valuable training in entrepreneurship.
Meet the 2024/2025 PCI Fellows Cohort
Eleven fellows were admitted to the 2023/2024 cohort out of a large application pool.
Penn’s Chief Innovation Officer John Swartley Interviewed by BioBuzz @ Philly Builds Bio+ Symposium and nominated for the Life Science Cares Leader of the Year Award
In the interview, Dr. Swartley talks about how he leads and supports innovation initiatives across Penn and his career in technology transfer.
Michael Kahana Featured in NY Post for Memory Research
Michael Kahana was recently featured in the New York Post for his cutting-edge research in memory recall.
Penn Engineering’s Shu Yang to Co-Design Artificial Reef Structures that Help Harness Wave Energy
Dr. Yang’s focus is developing low-cost and recycled carbonated materials that are safe for, and tolerant of, the marine environment.
Jay Z’s Shawn Carter Foundation in Collaboration with Coalition for Equity and Opportunity at Penn’s Wharton School, Launch ‘Champions for Financial Legacy’ Program for HBCUs
This partnership focuses on transforming Dr. Weigelt's community program, "Bridges to Wealth," into a broader initiative called "Champions for Financial Legacy."
Mitchell Lab Discovers Siloxane-Enhanced Nanoparticles and Refines LNPs to Advance mRNA Medicine
A group of researchers at Penn Engineering led by Michael Mitchell, PhD, Associate Professor in Bioengineering, have developed a method to direct lipid nanoparticles (LNPs) to target specific tissues.